Illumina Gains 'Early Penetration' into Clinical Markets as It Eyes More FDA Submissions | GenomeWeb

Illumina said this week that sales of its MiSeq system — including the US Food and Drug Administration-cleared MiSeqDx — its TruSight targeted panels, genomes ordered through its Fast Track services, and HiSeq 2500, are driving its sequencing technology into clinical markets.

"Our results clearly demonstrate the early penetration of NGS into reproductive health, oncology, and other clinical markets, and our improving competitive position," CEO Jay Flatley said during a conference call discussing the firm's 2013 fourth quarter results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.